PTX1(ERGIC2)-VP22 fusion protein upregulates interferon-β in prostate cancer cell line PC-3

DNA and Cell Biology

Volumn 25, Issue 9, 2006, Pages 523-529

  Kwok, Simon C M ^a   Liu, Xianhong ^a   Mangel, Patricia ^a   Daskal, Ierachmiel ^a  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CELL PROTEIN; ERGIC2 PROTEIN; ERV41P PROTEIN; HOMEODOMAIN PROTEIN; HYBRID PROTEIN; HYPOPHYSIS HORMONE; LEUCINE; METHIONINE; PITUITARY HOMEOBOX PROTEIN; PROTEIN VP22; PTX1 VP22 PROTEIN; UNCLASSIFIED DRUG; NUCLEAR PROTEIN; PTX1 PROTEIN, HUMAN;

ARTICLE; CELL LINE; CELL LINE PC 3; CONTROLLED STUDY; DNA SEQUENCE; ENDOPLASMIC RETICULUM; FUNCTIONAL PROTEOMICS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GOLGI COMPLEX; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENESCENCE; SUBTRACTIVE HYBRIDIZATION; UPREGULATION; CELL AGING; GENE EXPRESSION PROFILING; GENETIC TRANSFECTION; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

CELL AGING; CELL LINE, TUMOR; ENDOPLASMIC RETICULUM; GENE EXPRESSION PROFILING; HUMANS; INTERFERON-BETA; MALE; NUCLEAR PROTEINS; PROSTATIC NEOPLASMS; RECOMBINANT FUSION PROTEINS; TRANSFECTION; UP-REGULATION;

EID: 33750629956     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2006.25.523     Document Type: Article

References (20)

1. BENIMETSKAYA, L., WITTENBERGER, T., STEIN, C.A., HOFMANN, H.-P., WELLER, C., LAI, J.C., MILLER, P., and GEKELER, V. (2004). Changes in gene expression induced by phosphorothioate oligodeoxynucleotides (including G3139) in PC3 prostate carcinoma cells are recapitulated at least in part by treatment with interferon-β and -γ. Clin. Cancer Res. 10, 3678-3688.
2. BREUZA, L., HALBEISEN, R., JENO, P., OTTE, S., BARLOWE, C., HONG, W., and HAURI, H.-P. (2004). Proteomics of endoplasmic reticulum-Golgi intermediate compartment (ERGIC) membranes from Brefeldin A-treated HepG2 cells identifies ERGIC-32, a new cycling protein that interacts with human Erv46. J. Biol. Chem. 279, 47242-47253.
3. CAMPISI, J. (2001). Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol. 11, S27-S31.
4. DONG, Z., GREENE, G., PETTAWAY, C., DINNEY, C.P.N., EUE, I., LU, W., BUCANA, C.D., BALBAY, M.D., BIELENBERG, D., and FIDLER, I.J. (1999). Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-β. Cancer Res. 59, 872-879.
5. DU, W., and MANIATIS, T. (1992). An ATF/CREB binding site is required for virus induction of the human IFN-β gene. Proc. Natl. Acad. Sci. USA 89, 2150-2154.
6. GSCHWEND, I.E., FAIR, W.R., and POWELL, C.T. (1997). Evaluation of the tetracycline-repressible transactivator system for inducible gene expression in human prostate cancer cell lines. Prostate 33, 166-176.
7. HO, C.K.M., and STRAUSS, J.F., III (2004). Activation of the control reporter plasmids pRL-TK and pRL-SV40 by multiple GATA transcription factors can lead to aberrant normalization of transfection efficiency. BMC Biotechnol. 4, 10-14.
8. KAYNOR, C., XIN, M., WAKEHELD, J., BARSOUM, J., and QIN, X.-Q. (2002). Direct evidence that IFN-β functions as a tumor-suppressor protein. J. Interferon Cytokine Res. 22, 1089-1098.
9. KULAEVA, O.I., DRAGHICI, S., TANG, L., KRANIAK, J.M., LAND, S.J., and TAINSKY, M.A. (2003). Epigenetic silencing of multiple interferon pathway genes after cellular immortalization. Oncogene 22, 4118-4127.
10. KWOK, S.C.M., LIU, X., and DASKAL, I. (2001 ). Molecular cloning, expression, localization, and gene organization of PTX1, a human nuclear protein that is downregulated in prostate cancer. DNA Cell Biol. 20, 349-357.
11. LENARDO, M.J., FAN, C.M., MANIATIS, T., and BALTIMORE, D. (1989). The involvement of NF-κB in β-IFN gene regulation reveals its role as widely inducible mediator of signal transduction. Cell 57, 287-294.
12. LIN, R., GENIN, P., MAMANE, Y., and HISCOTT, J. (2000). Selective DNA binding and association with the CREB binding protein coactivator contribute to differential activation of α/β IFN genes by IFN regulatory factors 3 and 7. Mol. Cell. Biol. 20, 6342-6353.
13. LIU, X., DASKAL, I., and KWOK, S.C.M. (2003). Effects of PTX1 expression on growth and tumorigenicity of the prostate cancer cell line PC-3. DNA Cell Biol. 22, 469-474.
14. MANIATIS, T., WHITTEMORE, L.-A., DU, W., FAN, C.-M., KELLER, A.D., PALOMBELLA, V., and THANOS, D. (1992). Positive and negative regulation of the human interferon-β gene expression. In Transcriptional regulation. S.L. McKnight and K. Yamamoto, eds. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY) pp. 1193-1220.
15. NOURBAKHSH, M., and HAUSER, H. (1999). Constitutive silencing of IFN-β promoter is mediated by NRF (NF-κB-repressing factor), a nuclear inhibitor of NF-κB. EMBO J. 18, 6415-6425.
16. QING, J., LIU, C., CHOY, L., WU, R.-Y., PAGANO, J.S., and DERYNCK, R. (2004) Transforming growth factor β/Smad3 signaling regulates IRF-7 function and transcriptional activation of the beta interferon promoter. Mol. Cell. Biol. 24, 1411-1425.
17. SICA, G., FABBRONI, L., CASTAGNETTA, L., CACCIATORE, M., PAVONE-MACALUSO, M. (1989). Antiproliferative effect of interferons on human prostate carcinoma cell lines. Urol. Res. 17, 111-115.
18. SHOU, J., SORIANO, R., HAYWARD, S.W., CUNHA, G.R., WILLIAMS, P.M., and GAO, W.-Q. (2002). Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression. Proc. Natl. Acad. Sci. USA 99, 2830-2835.
19. WOLFE, M.S., and KOPAN, R. (2004). Intramembrane proteolysis: Theme and variations. Science 305, 1119-1123.
20. XIN, H., CURRY, J., JOHNSTONE, R.W., NICKOLOFF, B.J., and CHOUBEY, D. (2003). Role of IFI 16, a member of the interferon-inducible p200-protein family, in prostate epithelial cellular senescence. Oncogene 22, 4831-4840.